首页/数据集/Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

ChEBI2014-10-07 更新2026-07-21 收录

化疗耐药机制

肿瘤分子特征

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-62118 数据链接链接失效反馈

官方服务：

资源简介：

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

应用场景：

创建时间：

2014-10-07

头颈部鳞状细胞癌基因

化疗耐药机制

In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur

NIAID Data Ecosystem70

MRTF/SRF link the cytoskeleton and hedgehog pathway in drug-resistant basal cell carcinomas

化疗耐药机制

Hedgehog信号通路

We use multi-dimensional genomic analysis using mouse resistant BCCs to identify a non-canonical hedgehog activation pathway driven by the transcription factor, serum response factor (SRF). RNA and wh

NIAID Data Ecosystem50

DataSheet2_Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest.xlsx

化疗耐药机制

代谢重编程

The occurrence of cisplatin resistance is still the main factor limiting the therapeutic effect of non-small cell lung cancer (NSCLC). It is urgent to elucidate the resistance mechanism and develop no

NIAID Data Ecosystem40

Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in non-small cell lung cancer

化疗耐药机制

多组学整合分析

Continuous exposure to cisplatin can induce drug resistance to limit efficacy, however, the underlying mechanisms correlated to cisplatin resistance are still unclear. Drug-sensitive A549 cells and ci

NIAID Data Ecosystem70

Loss of IFN-g signaling in tumor cells associates with primary resistance to anti-CTLA-4 therapy

化疗耐药机制

IFN-γ信号通路

"Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-?,

NIAID Data Ecosystem40

Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations

资源简介：

相关数据集